FMMR Model for Overlapping Drug Cluster Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying cancer-specific therapeutic biomarkers and predicting drug resistance patterns are limited by their inability to handle complex data sets with overlapping clusters and interdependent drug responses, leading to insufficient prediction performance and lack of suitable models for overlapping clustering.
Innovation Solution
A finite mixture of multivariate regression (FMMR) model is developed, allowing for overlapping clustering and joint modeling of drug and genomic data, using a generalized finite mixture of multivariate regression (FMMR) model and the expectation-maximization (EM) algorithm to identify alternative drug therapies and group drugs effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional multivariate analysis of variance (MANOVA) is used to examine drug-genomic feature associations, then categorical features can be analyzed, but over 95% of continuous features are not examined and marginal associations rarely reflect true relationships
Solution Approach 1:
The patent transforms continuous genomic features into discrete clusters through unsupervised learning, changing the parameter representation from continuous values to cluster assignments. This enables the use of categorical analysis methods while preserving the underlying continuous information, thereby examining all features without losing precision in association detection
Solution Approach 2:
The patent introduces cluster assignments as an intermediary layer between continuous genomic features and drug response outcomes. This intermediary transformation allows continuous features to be analyzed using categorical methods while maintaining the ability to detect true relationships through the cluster structure
2Reliability
If elastic-net regression is applied to each drug to identify significantly related features, then adjustments for other effects can be made, but the complexity of the data and interdependencies among drugs are not adequately addressed
Solution Approach 1:
The patent merges the analysis of multiple drugs and genomic features into a unified clustering framework where all features are simultaneously considered. This combined approach captures interdependencies among drugs and features while maintaining reliable association detection through the joint clustering structure
Solution Approach 2:
The patent creates a universal clustering model that simultaneously handles multiple drugs, continuous features, and their interrelationships. This multi-functional approach replaces multiple separate elastic-net regressions with a single framework that addresses all data complexities at once
3Productivity
If cancer cell lines are used to screen therapeutic biomarkers with high throughput studies, then large-scale drug-genomic associations can be analyzed, but the ability to handle overlapping clusters and predict drug resistance patterns is insufficient
Solution Approach 1:
The patent implements dynamic cluster assignments where cell lines can belong to multiple overlapping clusters simultaneously, rather than being forced into single static categories. This dynamic approach captures the complexity of cancer biology and improves prediction of drug resistance patterns while maintaining high throughput screening capabilities
Data Source
AI summary
Computer-implemented processes for precision therapeutic biomarker screening for cancer include using a model-based overlapping clustering framework to assess large numbers of possible drugs and drug combinations against patient data, including cell line responsiveness. A multivariate regression model has been developed, along with a latent overlapping cluster indicator variable. The techniques employ a new finite mixture of multivariate regression (FMMR) model and expectation-maximization (EM) algorithm for modeling. The techniques can analyze large amounts of drug data and identify complex overlapping drug clusters, as well as cluster-wise drivers that facilitate identification of new drugs for treating pathologies, such as cancer, in patients.